Open Access

The course of metastatic prostate cancer under treatment

  • Aslan Demir1Email author,
  • Kursat Cecen1,
  • Mert Ali Karadag1,
  • Ramazan Kocaaslan1 and
  • Levent Turkeri2
SpringerPlus20143:725

https://doi.org/10.1186/2193-1801-3-725

Received: 24 July 2014

Accepted: 6 November 2014

Published: 10 December 2014

Abstract

The first-line management of metastatic prostate cancer is hormonal therapy. However, resistance to this treatment will emerge within an average of 24 months. Our purpose was to determine the course of metastatic prostate cancer under treatment.

A total of 56 patients who were diagnosed with metastatic prostate cancer were enrolled. As initial management, 3 kinds of hormonal therapy consisting of bilateral orchiectomy (BSO) alone, BSO + anti-androgene (AA) and LH-RH + AA were applied. The patients were followed until the emergence of hormone resistance. Serum PSA levels at the time of first diagnosis, post-treatment nadir PSA levels, time to nadir PSA, time to hormonal resistance and PSA levels at hormonal resistance were assessed, retrospectively. The localization and number of metastases and the survival term from the beginning of the emergence of hormone resistance until death were investigated

No significant differences could be established between the groups. The mean time to reach hormone refractory status was 30.3 months for the whole study group. The average term of survival was 42.7 months for the whole group. Distance metastases were found in 8 patients during follow-up.

There were no statistical differences between the groups in terms of treatment modalities applied for metastatic prostate cancer. Patients with androgen independent prostate cancer demonstrated progression despite chemical or surgical castration, and had poor prognosis. Initial hormonal therapy failed after an average of 2 years in metastatic prostate cancer.

Keywords

Metastatic prostate cancer Treatment modality Course

Background

Most of the prostate cancers (PCa) are, at least at the beginning, endocrine-dependent tumors. Therefore, hormonal therapy is still a first-choice treatment (Chen et al. 2008). The first effects to hormonal treatment with medical or surgical castration are quite considerable, with rapid biochemical responses, as evaluated by declines in levels of the serum marker, prostate-specific antigen (PSA) (Di Lorenzo et al. 2010; Chi et al. 2009). However, most patients showing a first response to hormonal therapy for PCa will progress to a castration-insensitive phase of the disease that continues a much poorer prognosis (Chi et al. 2009).

The true is that androgens have an important role in the whole clinical course of Pca, even when a patient meets castration-resistance criteria (Pinto 2013). Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are of considerable roles in PCa progression. Specifically, LH expression in PCa tissues has been associated with metastatic disease with a poor prognosis, while FSH has been related to stimulate prostate cell growth in hormone-refractory PCa (Kluth et al. 2013). Endocrine therapy is the standard treatment for metastatic PCa, but in its progess an androgen independence status can occurs. As endocrine management, primary androgen deprivation therapy (ADT) is the standard of care, usually with a long-releasing LHRH analogue or antagonist (Pagliarulo et al. 2012).

The aim of our study was to determine the course of the disease in patients with initial metastatic PCa.

Results

A total of 56 patients were enrolled. In this study, the median age of the patients was 70 (min. 59 – max. 93). BSO alone was performed in 12 patients (21.7%), adjunctive antiandrogen therapy was given to 18 patients (32.05%) and LH-RH analogues combined with antiandrogen therapy were given to 26 patients (46.1%). No statistically significant differences could be established between the groups according to the parameters of our study (Table 1). The mean PSA (ng/ml) values before treatment were 171, 383.7, and 626.5, respectively. The Gleason Scores (GS) of all groups were 7. The mean time to the emergence of hormone refractory status was found to be 30.3 months for the whole study group. The average survival was 42.7 months (min. 9-max. 120) in the whole group. Mean survival time (month) were 45, 45.25, and 34.25, respectively. Distance metastases were found in 8 patients during follow-up. The prognosis of these patients was poor.
Table 1

The summary of the results of each treatment group

Parameters

BSO n = 12

BSO + AA n = 18

LH-RH + AA n = 26

WHOLE GROUP n = 56

 

Median

Mean

Median

Mean

Median

Mean

Median

Mean

The PSA (ng/ml) values before teratment

91

171

143

383,7

115

626,5

110

423,8

Gleason score

7

7,33

7

7,5

7

7,52

7

7,4

The nadir PSA (ng/ml) after treatment

1,3

31,01

3,6

37,47

2,4

7,87

2,71

21,68

The time to the nadir PSA (months)

3

5,9

4,5

6,45

8,5

9,27

6

7,44

The time to hormonal resistance (months)

18,7

32,77

17

26,48

21

27,3

20

30,28

The PSA (ng/ml) at the hormonal resistance

103,5

124,2

54

163,7

38,5

890,6

54

489,9

Survival (months)

25

45

47

45,25

32

34,35

34

42,67

All p values >0,05.

Discussion

Monotherapy and combined therapy are the hormonal management modalities. The first one contains castration or anti-androgens treatment, and the second one includes maximum or complete androgene blockage (MAB or CAB) with castration (medical or surgical) and anti-androgens. However, a refractory status to these treatment will progress within an average of 2 years. Poor prognosis and death from the disease within 18–24 and 22 months have been reported by some researchers in the literature (Crawford et al. 1989; Kelly et al. 2010) but in the beginning, estimates of median survival for patients with hormone-refractory PCa were 7–12 months (Hussain et al. 1994). When the patients progress in front of continued androgen ablation, they are named to have hormone-refractory prostate cancer or metastatic castrate-resistant prostate cancer (mCRPC) (Martel et al. 2003).

Most patients with PCa at the organ confined level have an excellent prognosis after radical prostatectomy and/or radiation therapy. A significant fraction (20%-40%) of patients who undergo primary therapy experience biochemical progression, and 30–70% of those with biochemical relapse progress to the metastatic status within 10 years after local management (Pound et al. 1999). Usually, patients with hormone-refractory PCa may apply with symptoms associated with metastases, especially bone, lymph nodes and other urinary metastases, but the first sign is generally, an increased PSA levels despite to the treatment (Martel et al. 2003; Sammon et al. 2013).

The population of PCa with distant metastasis is heterogeneous (European Association of Urology Guidelines 2013). One of the poor prognostic factors was the PSA level greater than 65 ng/ml (Chi et al. 2009). According to the results of our study, mean PSA (ng/ml) values before treatment were 171, 383.7, and 626.5, respectively. The GS of all groups in our study were 7.

The choice between orchiectomy and oestrogens are the standard treatment for advanced PCa (Murphy et al. 1983; Sharifi 2009). It is well known that the initial development of PCa is dependent on androgens; therefore, the first-line management of this situation is endocrine management. First-line treatment for advanced PCa is ADT, usually with agents that inhibates gonadotropins through a pituitary mechanism. Gonadotropin-releasing hormone agonists and antagonists both inhibates gonadal release of testosterone, although their activity profiles differ (Murphy et al. 1983; Kluth et al. 2013).

ADT down-regulates the androgen receptor (AR) in the tumor but the response in advanced disease is not permanent, a progression may occur as CRPC. Although serum testosterone levels decrease significantly with ADT, CRPC development largely depends on AR activity (Sharifi 2009). Secondary hormonal therapies are then often used to further lessen AR-driven. These secondary hormonal managements either further deplete adrenal or intratumoral androgens synthesis, or directly and competitively antagonize AR (Sharifi 2009).

The median survival time for patients with metastatic androgen-independent PCa is approximately 1 or 2 years (Hussain et al. 1994; Kelly et al. 2010). In most studies in the literature, no statistically significant differences have been reported between the results of different hormonal treatment modalities that are performed in metastatic PCa. The results of our study are similar to those in the literature. The Median and mean survival time (month) in our study were 25/45, 47/42.25, and 32/34.35, respectively.

Robinson et al. compared the alternatives of orchiectomy and maximal androgen blockage with 1 mg diethylstilbestrol (DES) in 1995 and declared no difference in terms of progression rate and survival between the two groups (Robinson et al. 1995). In another study conducted by Mikkola et al., orchiectomy and parental polyestradiol phosphate were compared and no difference was reported in terms of progression and survival follow-up for 2 years (Mikkola et al. 1998). Laufer et al. found no benefits in the use of combined androgen blockade (CAB) with medical or surgical castration (Laufer et al. 2000). In addition, a non-steroidal antiandrogen for metastatic PCa was investigated in 20 randomized trials by Crawford et al. which led to the finding that there is a 5% improvement in the percentage of men surviving 5 years (30% vs. 25%) with combined androgen blockade with nonsteroidal antiandrogens, as well as improvements in progression-free survival at 1 year (Crawford et al. 1989).

The patients with metastatic PCa ought to be informed of the potential benefits, toxicities and out-of pocket expenditures about managements modalities (Schmitt et al. 2001; Prostate Cancer Trialists’ Colloborative Group 2000). Gastrointestinal, ophthalmological and hematological side effects are worse with CAB. Although LHRH analogues and non-steroidal anti-androgens have the highest estimated quality-adjusted survival, there is an increased cost of more than US$1 million per quality-adjusted life-year for CAB over orchiectomy alone (European Association of Urology Guidelines 2013). In a SWOG study published in 1998, although there was no statistical difference, using MAB decreased the risk of mortality about 9% compared with orchiectomy alone. In addition, two meta-analyses have declared that there is an increase in response rate using MAB with non-steroidal antiandrogen compared to mere castration (Prostate Cancer Trialists’ Colloborative Group 2000; Caubet et al. 1997). On the other hand, the same studies mentioned that there was also an increase in time to progression when using MAB with non-steroidal antiandrogen compared with other managements (Caubet et al. 1997; Glashon & Robinson 1981).

Fossa et al. have mentioned responses to flutamide in some patients in whom previous endocrine managements failed, and found that this correlated with increased survival (Fossa et al. 1990). On the other hand, Andrew et al. have established that orchiectomy as a secondary hormonal management following relapse on antiandrogen does produce a response in terms of PSA level and symptoms in some patients (Andrew et al. 2001). In the only published randomized controlled trials (RCT), there was no significant difference in OS for flutamide monotherapy compared in bone metastatic patients with a PSA <100 ng/ml. But at a higher PSA, flutamide was inferior. (European Association of Urology Guidelines 2013).

Bicalutamide, 150 mg once daily, it has been compared to medical or surgical castration in two large prospective RCTs with identical study designs, including patients with locally advanced or metastatic PCa; the analysis found that in metastatic patients, there was an improvement in OS with medical or surgical castration, although the difference in median survival between the groups was only 6 weeks (Tyrrell et al. 1998).

According to our results, there is no statistical difference in terms of survival between the hormonal treatment modalities that have been applied for metastatic PCa in the literature, but we must pay attention to the status of each patient with advanced PCa, such as psychological state and tolerance to the side effects of the treatment modalities, since the quality-of-life is paramount. Antiandrogen therapy has remained the mainstay in the treatment of metastatic PCa. To reduce the testosterone level in blood, both oestrogens and bilateral orchiectomy can be use effectively (Martel et al. 2003). However, oestrogens have obvious disadvantages and particularly cardiovascular, even life-threatening, side effects need to take into the consideration (Glashon & Robinson 1981). On the other hand, the underestimation of the psychological side effects of bilateral orchiectomy is possible. Therefore, the advantages of LH-RH analogues have led to the new views in the management of PCa. Superactive LH-RH analogues effectively reduce plasma testosterone to castrate levels (Jacobi & Wenderoth 1982). Therefore, these drugs can be considered as the first choice alternatives to oestrogens or orchiectomy, but we believe that not only is cost-effectiveness an important issue that should be considered for patients who do not have any health insurance, but the socio-cultural level of patients is also important in terms of accommodation to the treatment. Namely, if the socio-cultural and economic level of the patient is low, then BSO may be the first choice for treatment.

In addition to these findings, the development of a hormone-refractory state in patients with advanced PCa is inevitable. Initial androgen ablation can provide, on average, 18 months of biochemical response. There has been an interest in utilizing antiandrogen monotherapy in these patients initially to preserve quality-of-life.

If the biochemical relapse does occur under treatment of antiandrogen monotherapy, to know whether further hormonal manipulation will provide any benefit is important. Scher et al. have declared that patients who had a biochemical relapse on maximal androgen blockade and then had a response to antiandrogen withdrawal, had a further response to the addition of a different antiandrogen (Scher et al. 1997). It has been suggested that stopping of androgen deprivation before the progression of androgen resistant situation would mean that any subsequent tumor growth would be sustained by the proliferation of androgen-sensitive stem cells. The stem cells should therefore be susceptible one more time to androgen withdrawal. Thus, intermittent androgen blockade (IAD) would postpone the emergence of the androgen-resistant clone. In addition, preservation of quality-of-life of patients under IAD treatment will occur in terms of better tolerance of treatment; sometimes benefits in sexual function in off-treatment periods and reduction in the cost of treatment will be provided. However, IAD has not been reported to be related to prolonged hormone-sensitive status or an increase in OS (European Association of Urology Guidelines 2013).

We know that, currently, there is no standard front-line or second line therapy for these hormone refractory patients. For that reason, we must pay attention the patients’ quality-of-life when deciding on the method of treatment. At this point, the expectations of the patients are of great importance. In our opinion, treatment modalities that have reversible side effects should be chosen in order to evaluate the tolerance of the patients at the beginning of management. For that reason, medical treatment modalities should be chosen primarily in order to avoid the psychological side effects of surgery such as empty scrotum, hot flashing, etc.

Average survival of patients with metastatic PCa following relapse who do not undergo further treatment is 14 months (Matzkin et al. 1993). Unfortunately, despite all treatments, treatment failure occurs within 2 years of initial management. Treatment options for hormone refractory disease include intensive supportive care, radiotherapy, biphosphonates, second-line hormonal manipulations, cytotoxic chemotherapy and investigational agents. Chemotherapeutic agents have yielded improved response rates and palliative benefit, but not improved survival (Hussain et al. 1994; Murphy et al. 1983; Kantoff et al. 1999; Robinson et al. 1995). Therefore, new studies must focus on new agents in order to improve survival, time to progression and quality-of-life. We also believe that psychological support should be given at the time of progression to the hormone refractory stage for the sake of quality-of-life.

Conclusion

As a conclusion; according to our results, there was no statistical difference between the hormonal treatments that were applied in metastatic prostate cancer in terms of the above mentioned parameters. Patients with androgen independent prostate cancer demonstrate progression of the disease despite chemical or surgical castration, and have poor prognosis.

Methods

A database of 56 patients who had a metastatic PCa diagnosis and received hormonal therapy as initial management, which was applied until the emergence of hormone resistance, was retrospectively reviewed in order to understand the course of the disease. The patients were categorized into 3 groups according to the type of applied treatment modality. These groups comprised bilateral subcapsular orchiectomy (BSO) alone, bilateral subcapsular orchiectomy combined with anti-androgen therapy, and LH-RH combined with anti-androgen. One of these treatment modalities was applied to the patients as initial management. Serum PSA levels at the time of the first diagnosis, post-treatment nadir PSA levels, time to nadir PSA, time to hormonal resistance and PSA levels at hormonal resistance were assessed retrospectively. In addition to these, the localization and number of metastases and the term of survival from the beginning of the emergence of hormone resistance until death were investigated.

Statistical analysis

One-way ANOVA test, a parametric statistical test, was used to compare the three groups with respect to the normally distributed variables in our data. A probability level of p < 0.05 was considered as significant.

Abbreviations

Pca: 

Prostate cancer

PSA: 

Prostate specific antigen

ADT: 

Androgen deprivation therapy

MAB: 

Maximum androgen blockage

CAB: 

Complete androgen blockage

mCRPC: 

Metastatic castrate-resistant prostate cancer

BSO: 

Bilateral subcapsular orchiectomy

GS: 

Gleason score

ECOG: 

Eastern countries oncology group

SWOG: 

Southwest oncology group

AR: 

Androgen receptor

DES: 

Diethylstillbestrol

RCT: 

Randomized controlled trials

OS: 

Overall survival

IAD: 

Intermittent androgen blockade.

Declarations

Authors’ Affiliations

(1)
Department of Urology, Kafkas University Faculty of Medicine
(2)
Department of Urology, Marmara University Faculty of Medicine

References

  1. Andrew T, Tuckey J, Rice M: Orchidectomy following failure of antiandrogen monotherapy in patients with metastatic prostate cancer. Eur Urol 2001, 40: 130-134. 10.1159/000049762View ArticleGoogle Scholar
  2. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD: Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997, 49: 71-78. 10.1016/S0090-4295(96)00325-1View ArticleGoogle Scholar
  3. Chen Y, Sawyers CL, Scher HI: Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008, 8: 440-448. 10.1016/j.coph.2008.07.005View ArticleGoogle Scholar
  4. Chi KN, Bjartell A, Dearnaley D, Saad F, Schroder FH, Sternberg C, Tombal B, Visakorpi T: Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009, 56: 594-605. 10.1016/j.eururo.2009.06.027View ArticleGoogle Scholar
  5. Crawford E, Eisenberger M, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Gutman PJ: A controlled randomized trial of leuprolid with and without flutamide in prostatic cancer. N Eng J Med 1989, 321: 419-424. 10.1056/NEJM198908173210702View ArticleGoogle Scholar
  6. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN: Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010, 70: 983-1000. 10.2165/10898600-000000000-00000View ArticleGoogle Scholar
  7. European Association of Urology Guidelines: Update March 2013, Section 13. Metastatic Prostate Cancer-Hormonal Therapy. 2013, 86.Google Scholar
  8. Fossa SD, Hosbach G, Paus E: Flutamide in hormone-resistant prostate cancer. J Urol 1990, 144: 1411-1414.Google Scholar
  9. Glashon RW, Robinson MRG: Cardiovascular complications in the treatment of the prostatic carcinoma. Br J Urol 1981, 53: 624. 10.1111/j.1464-410X.1981.tb03276.xView ArticleGoogle Scholar
  10. Hussain M, Wolf M, Marsall E, Crawford ED, Eisenberger M: Effects of continued androgen deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group Report. J Clin Oncol 1994, 12(9):1868-1875.Google Scholar
  11. Jacobi GH, Wenderoth U: Gonadotropin releasing hormone analogues for prostate cancer: untoward side effects of high dose regimens acquire a therapeutical dimension. Eur Urol 1982, 8(3):129-134.Google Scholar
  12. Kantoff PW, Halabi S, Conaway M, Picus J, Kirsner J, Hars V, Trump D, Winer EP, Vogelzang NJ: Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17: 2506-2513.Google Scholar
  13. Kelly WK, Halabi SI, Carducci MA, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ: Randomized, double-blind, placebo controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012, 30(13):1534-40. 10.1200/JCO.2011.39.4767View ArticleGoogle Scholar
  14. Kluth LA, Shariat SF, Kratzik C, Tagawa S, Sonpavde G, Rieken M, Scher DS, Pummer K: The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol 2013, 32(3):669-676.View ArticleGoogle Scholar
  15. Laufer M, Denmead SR, Sinibaldi VJ, Carducci MA, Eisenberger MA: Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000, 164: 3-9. 10.1016/S0022-5347(05)67436-8View ArticleGoogle Scholar
  16. Martel CL, Gumerlock PH, Meyers FJ, Lara PN: Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003, 29: 171-187. 10.1016/S0305-7372(02)00090-7View ArticleGoogle Scholar
  17. Matzkin H, Rangel C, Soloway M: Relapse on endocrine treatment in patients with stage D2 prostate cancer. Urology 1993, 41: 144-148. 10.1016/0090-4295(93)90167-9View ArticleGoogle Scholar
  18. Mikkola AK, Ruutu ML, Aro JL, Rannikk SA, Salo JO: Parenteral polyestradiol phosphate vs orchiectomy in the treatment of the prostatic cancer. Efficacy and cardiovascular complications: a 2-years follow-up report of a national, prospective cancer study. Br J Urol 1998, 82: 63-68. 10.1046/j.1464-410x.1998.00688.xView ArticleGoogle Scholar
  19. Murphy GP, Beckly S, Brady MF, Chu TM, deKernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormone alone. Cancer 1983, 51: 1264-1272. 10.1002/1097-0142(19830401)51:7<1264::AID-CNCR2820510716>3.0.CO;2-UView ArticleGoogle Scholar
  20. Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schroder FH, Sternberg CN, Studer UE: Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012, 61(1):11-25. 10.1016/j.eururo.2011.08.026View ArticleGoogle Scholar
  21. Pinto A: Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer Biol Ther 2013, 15(2):149-155.View ArticleGoogle Scholar
  22. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(17):1591-1597. 10.1001/jama.281.17.1591View ArticleGoogle Scholar
  23. Prostate Cancer Trialists’ Colloborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000, 355(9214):1491-1498.View ArticleGoogle Scholar
  24. Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R: The final analysis of the EORTC Genito-Urinary Tract Cancer Co-operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetat and low dose stilboestrol in the management of the metastatic carcinoma of the prostate. Eur Urol 1995, 28(4):273-283.Google Scholar
  25. Sammon JD, Kaczmarek BF, Ravi P, Sun M, Roghman F, Sukumar S, Ghani K, Sharma P, Karakiewicz PI, Peabody JO, Elder JS, Menon M, Trinh QD: Effect of metastatic site on emergency department disposition in men with metastatic prostate cancer. Can J Urol 2013, 20(6):7008-7014.Google Scholar
  26. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997, 15: 2928-2938.Google Scholar
  27. Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, Bennet CL: Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001, 57(4):727-732. 10.1016/S0090-4295(00)01086-4View ArticleGoogle Scholar
  28. Sharifi N: Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function. Anticancer Agents Med Chem 2009, 9(10):1046-1051. 10.2174/187152009789735044View ArticleGoogle Scholar
  29. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G: A randomized comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998, 33(5):447-456. 10.1159/000019634View ArticleGoogle Scholar

Copyright

© Demir et al.; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.